EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic and Clinical Features in TP53 ‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data

Yanming Cheng iD, Lixia Liu iD, Yu Gao iD, Yifei Wang iD, Wei Zhu iD, Hong Chen iD, Jiayue Qin iD, Yudi Zhang iD

Cancer Reports · 2026-06 · 9 (6)

DOI: 10.1002/cnr2.70584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 29.05.2026. Verfasst von Yanming Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Tumor Suppressor Protein p53, Mutation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53 ‐mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi‐hit classification. Literatures indicate that TP53 variant alle frequency (VAF) correlates with clinical outcomes. However, comprehensive studies that characterize the full mutation landscape and clinical correlations in Asian populations are still limited.

Aims

This research aims to elucidate the mutation spectrum and baseline characteristics of TP53 ‐mutated MDS in a Chinese cohort, thereby enhancing clinical understanding and treatment approaches. Methods and Results A total of 161 TP53 ‐mutated patients from 1589 newly diagnosed MDS with next‐generation sequencing (NGS) data via a targeted 96‐gene sequencing panel were analyzed to assess genomic alterations. Among 161 TP53 ‐mutated patients (10.1% of 1589 MDS cases), we identified a predominance of missense mutations (76.9%) and frequent co‐occurrence with epigenetic modifiers, notably DNMT3A (11.8%), TET2 (10.6%), and ASXL1 (9.3%). Critically, TP53 VAF correlated strongly with disease severity parameters, including hemoglobin levels, blast percentage, karyotype, and International Prognostic Scoring System (IPSS), revised IPSS (IPSS‐R) risk and IPSS‐Molecular (IPSS‐M) classifications (all p < 0.05), suggesting that TP53 VAF serves as an important biomarker for risk stratification. In addition, patients with multiple TP53 mutations harbored significantly worse IPSS, IPSS‐R, and IPSS‐M risk classifications compared to those with a single TP53 mutation.

Conclusions

This study underscores the importance of TP53 mutations in Asian MDS patients, contributing to genetic profiling in risk stratification and therapeutic decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesTumor Suppressor Protein p53MutationHumansHigh-Throughput Nucleotide SequencingFemaleRetrospective StudiesMaleAgedMiddle AgedDNA Methyltransferase 3AAdultAged, 80 and overDioxygenasesPrognosisDNA (Cytosine-5-)-MethyltransferasesDNA-Binding ProteinsRepressor Proteins

Stichwörter der Autor:innen

MDSNGSTP53 mutationclinical features

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanDNA Methyltransferase 3ATET2 protein, humanDNMT3A protein, humanDioxygenasesASXL1 protein, humanDNA (Cytosine-5-)-MethyltransferasesDNA-Binding ProteinsRepressor Proteins

Autor:innen und Institutionen

  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Medical Affairs, Acornmed Biotechnology Co. Ltd., Beijing, China.
  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Cancer Center, Zhejiang University, Hangzhou, China.
  • Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.

ORCID-Profile: Yanming Cheng, Lixia Liu, Yu Gao, Yifei Wang, Wei Zhu, Hong Chen, Jiayue Qin, Yudi Zhang

Zitieren

APA

Cheng, Y., Liu, L., Gao, Y., Wang, Y., Zhu, W., Chen, H., Qin, J., & Zhang, Y. (2026). Genetic and Clinical Features in TP53 ‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data. Cancer Reports, 9(6). https://doi.org/10.1002/cnr2.70584

Vancouver

Cheng Y, Liu L, Gao Y, Wang Y, Zhu W, Chen H, et al. Genetic and Clinical Features in TP53 ‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data. Cancer Reports. 2026;9(6). doi:10.1002/cnr2.70584

BibTeX
@article{Cheng2026,
  author = {Cheng, Yanming and Liu, Lixia and Gao, Yu and Wang, Yifei and Zhu, Wei and Chen, Hong and Qin, Jiayue and Zhang, Yudi},
  title = {Genetic and Clinical Features in TP53 ‐Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next‐Generation Sequencing Data},
  journal = {Cancer Reports},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/cnr2.70584}
}
Kostenlos starten →